[stock_market_widget type=”card” template=”basic2″ assets=”ALVO” realtime=”true” api=”yahoo-finance”]
Biotech investors spend so much time watching clinical trial calendars that they can lose sight of a simpler question: does the company have enough cash to make it to the next milestone. That question got a clear answer today when Alvotech S.A. (NASDAQ: ALVO), an Iceland based biopharmaceutical company, said it had amended its existing credit agreement to add a $75 million term loan facility. It is not a flashy announcement, and it will not move a stock price the way a drug approval can, but for a company juggling nearly 30 biosimilar programs at once, it is the kind of news that quietly shapes how much risk shareholders are actually taking on.
The new loan, arranged with funds managed by GoldenTree Asset Management and other existing lenders, carries an interest rate of 12.50%, paid monthly in cash, and matures on December 31, 2027. It builds on a $100 million term loan facility the company put in place in December 2025, meaning Alvotech now has two layers of debt financing from the same lending group. The timing is notable. Just two weeks earlier in mid June, Alvotech closed a $165 million equity capital raise, bringing in more than 40 new specialist healthcare investors alongside existing shareholders. Combine that equity raise with the newly available, undrawn loan facility, and the company says it now has access to $240 million in fresh capital.
For a company still working through regulatory approvals and building out manufacturing capacity, that kind of cushion changes the calculus for shareholders. Biosimilar companies like Alvotech do not earn revenue the way a typical growth stock does. Their value depends heavily on hitting regulatory and commercial milestones across a pipeline of many products at once, and on having enough cash on hand to reach those milestones without needing to sell more shares at a discount along the way. Every time a company issues new equity to raise money, existing shareholders own a smaller slice of the business. Reducing the likelihood of that near term dilution is itself considered a positive signal in small and mid cap biotech circles, separate from anything happening in a lab.
Alvotech’s pipeline currently includes roughly 30 biosimilar products in various stages of development, according to the company. Among the higher profile programs is AVT33, a proposed biosimilar to Keytruda, the cancer immunotherapy sold by Merck (NYSE: MRK), which generated close to $30 billion in worldwide sales in 2024. Alvotech is co developing AVT33 with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) under an agreement signed in 2025. The company has also recently resubmitted key Biologics License Applications to the U.S. Food and Drug Administration and secured FDA acceptance of an application for a biosimilar to Entyvio, another widely prescribed biologic drug.
Robert Wessman, founder and chairman of Alvotech, framed the loan as a way to give the company more room to operate while it works through that pipeline, pointing to the support of both longtime shareholders and new healthcare focused investors in the recent stock offering. Industry watchers may read the move less as a headline event and more as routine balance sheet management, the kind of unglamorous work that rarely makes news on its own but tends to matter a great deal when a regulatory decision or product launch does not go exactly as planned.
None of this changes the underlying risk that comes with owning shares in a company built around biosimilars. The new debt adds to Alvotech’s obligations, and a 12.50% interest rate is not cheap money by most standards. Investors will still want to watch how the FDA responds to the company’s pending applications and how quickly its newer products reach the market. But for shareholders who worry about being diluted every few months by another stock sale, a fully funded runway through the next several product decisions offers a measure of breathing room that the market tends to notice, even when the news itself involves nothing more exciting than a loan agreement.
